A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma

Trial Profile

A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Mesothelioma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2020.
    • 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top